3-cell function, transgenic mice utilizing the rat insulin promoter to drive expression of Shb were generated. Materials and Methods: A gene construct allowing the Shb cDNA to be expressed from the rat insulin 2 promoter was microinjected into fertilized mouse oocytes and implanted into pseudopregnant mice. Mice containing a low copy number of this transgene were bred and used for further experimentation. Shb expression was determined by Western blot analysis. The insulin-positive area of whole pancreas, insulin secretion of isolated islets and islet cell apoptosis, glucose tolerance tests, and in vivo sensitivity to multiple injections of the 13-cell toxin streptozotocin were determined in control CBA and Shb-transgenic mice. Results: Western blot analysis revealed elevated islet content of the Shb protein. Shb-transgenic mice displayed enhanced glucose-disappearance rates in response to an intravenous glucose injection. The relative pancreatic (-cell area neonatally and at 6 months of age were increased in the Shb-transgenic mice. Islets isolated from Shb-transgenic mice showed enhanced insulin secretion in response to glucose and increased insulin and DNA content. Apoptosis was increased in islets isolated from Shb-transgenic mice compared with control islets both under basal conditions and after incubation with IL-1,B + IFN-,y. Rat insulinoma RINm5F cells overexpressing Shb displayed decreased viability during culture in 0. 1 % serum and after exposure to a cytotoxic dose of nicotinamide. Shb-transgenic mice injected with multiple doses of streptozotocin showed increased blood glucose values compared with the corresponding controls, suggesting increased in vivo susceptibility to this toxin. Conclusion: The results suggest that Shb has dual
Introduction
The adult pancreatic ( cell has a limited capacity for regeneration, and this could be of rele-main-containing adaptor protein Shb from /3TC-1 cells (3). Although we have subsequently demonstrated molecular interactions of the Shb SH2 domain with the platelet-derived growth factor (PDGF) /3-receptor, the fibroblast growth factor (FGF) receptor-i, and the T cell receptor (4, 5) , the Shb proline-rich motifs with Src, Eps8, p85 P13-kinase, and Grb2 (4, 5) , and the central phosphotyrosinebinding (PTB) domain with p36/38 in Jurkat T cells (5) , the physiological significance of Shb remains elusive. Shb overexpression in NIH3T3 cell fibroblasts causes increased rates of apoptosis upon serum withdrawal, an effect counteracted by PDGF (6) . Furthermore, Shb plays a role for T cell receptor signaling in Jurkat T cells (5) , whereas Shb overexpression in neuronal PC12 cells enhances growth factor-induced differentiation (7) . Thus Islet Isolation and Further Experimentation Islets were isolated from control CBA or RIP1-Shb transgenic 3-month-old mice of both sexes and cultured for 18 hr in the presence of 1 or 10% fetal calf serum (FCS) with or without the addition of cytokines [25 U/ml of human IL-I,B (PeproTech, London, UK) + 1000 U/ml of murine IFN--y (R&D Systems, Abingdon, UK)]. The islets were then used for determination of insulin secretion, insulin content, DNA content, and apoptosis by TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling) staining (12) (13) (14) (15) . The percentage of insulin-positive relative to total pancreas area was determined at day 1 after birth or at the age of 6 months by staining sections for insulin using an unlabeled peroxidase-antiperoxidase technique (16) . The insulin-positive area was determined on one cross section each from four to five different neonatal pancreata, and three cross sections from different regions (caput, corpus, and cauda) of each 6-month-old pancreas, using a computerized image analysis system for morphometry (MOP Videoplan, Kontron Bildanalyse, Munich, Germany). Labeling index of insulin-positive cells in vivo was also assessed at the age of 3 months (17).
A. 10 ,ug/ml propidium iodide and 20 ,ug/ml Hoechst 33342, after which the cells were inspected in a fluorescence microscope using a UV-2A filter.
Injections of Multiple Doses of Streptozotocin
Shb-transgenic and CBA control mice of both sexes and 3 months of age were injected intraperitoneally with five daily doses of 40 mg/kg body mass streptozotocin or saline (0.2 ml).
Blood glucose values were determined weekly, starting with the first injections. At 3 weeks, the animals were killed and pancreatic insulin content was determined after acid ethanol extraction from a weighed part of the retrieved pancreata.
-55 kDa Shb (Fig. 1C) . Western blot analysis of islet lysates revealed a comparable degree of Shbprotein overexpression in Shb-transgenic mouse islets from both lineages A and B when compared with CBA control islets (Fig. IC) , supporting the view that the Shb-transgenic phenotype is independent of the site of transgene integration.
Glucose Homeostasis
The basal blood glucose levels of control CBA and Shb-transgenic mice of both sexes was similar and below 8 mM in both groups of animals. Glucose injection caused a rapid increase in blood glucose to above 25 mM at 10 min after administration (Fig. 2A) . The blood glucose rapidly diminished after this time point, and the Shb-transgenic mice displayed a significantly lower blood glucose value at 30 min after injection than the CBA control. The calculated glucose disappearance rate (18) of the Shb-transgenic mice was 5.5 ± 0.8% per min; the corresponding value for the CBA control mice was significantly lower (3.0 ± 0.4% per min; p < 0.05). Like the enhanced blood glucose disappearance rates of the 3-monthold Shb-transgenic mice, 6-month-old Shbtransgenic mice displayed significantly lower blood glucose values at 10 min after glucose injection (Fig. 2B) islets at 3 months of age compared with the corresponding CBA control islets (Table 2) . However, when calculating the insulin per DNA content, near-equal values were noted ( Table 2 ). The insulin secretion of Shb-transgenic islets is shown in Figure 3 . Insulin secretion in the presence of 1.7 mM glucose was similar in all experimental groups irrespective of cytokine addition. The incubation at 16.7 mM glucose increased the secretion of insulin regardless of whether islets from CBA control or Shb-transgenic mice were used (Fig. 3) . However, the secretion of insulin at 16.7 mM glucose was significantly elevated in the Shbtransgenic islets compared to that of the CBA control. Culture of the islets in the presence of the cytokines IL-13 + IFN-'y significantly reduced the secretion of insulin in the presence of 16.7 mM glucose in both groups of islets (Fig. 3) . (Fig. 4) (Fig. 5B) . The proliferation of RIN-Shb cells compared with control transfected cells (RIN-neo) was determined in 10% serum (Fig. 5C ). Both clones proliferated rapidly and no signs of decreased rates of proliferation in the RIN-Shb cells were detected. Performing the same experiments in the presence of 0.1% serum yielded different results (Fig. 5D ). Whereas the cell numbers were similar for the first 48 hr in the RIN-neo and RIN-7 Shb cells, the number of RIN-Shb cells decreased after 72 and 96 hr compared with the initial 24-hr value (Fig. 5D) (20) . We decided to test the susceptibility of Shb-transgenic mice to this treatment. Control CBA and Shb-transgenic mice of both sexes and 3 months of age were injected with five doses of streptozotocin, which was followed by the development of hyperglycemia (Fig. 6A) . The blood glucose levels at 1, 2, and 3 weeks after the start of injections were significantly higher in the Shb-transgenic mice (Fig. 6A) . With regard to susceptibility to streptozotocin in these experiments, the Shb-transgenic mice of both sexes seemed to increase their blood glucose levels compared with the corresponding controls; the differences between male and female susceptibility failed to reach statistical significance except for male mice 1 week after the start of the injections (Fig. 6B) . The pancreatic insulin content (pmol insulin/mg pancreas) was markedly reduced 3 weeks after starting the streptozotocin treatment in both CBA (p < 0.001) and Shb-transgenic (p < 0.001) mice compared to corresponding controls [Shb-transgenic: 48.3 ± 4.0 (n = 8); Shb-transgenic + streptozotocin:
14.8 ± 2.8 (n = 10); CBA: 54.5 ± 4.8 (n = 8); CBA + streptozotocin: 24.5 ± 3.0 (n = 11)]. The insulin content in the transgenic mice appeared to be lower than in the CBA mice after streptozotocin administration, but this difference did not attain statistical significance (p < 0.06 using ANOVA). These results thus suggest increased ,B-cell destruction in vivo in response to streptozotocin in the Shb-transgenic islets.
Discussion
In order to obtain an understanding of the role of Shb protein for ,B-cell function in vivo, Shb cDNA was placed under the control of rat insulin 2 promoter and used to create transgenic mice. The Shb expression level in islets isolated from such transgenic mice was moderately elevated, and a similar degree of Shb overexpression has previously been observed in NIH3T3 cells (6) or PC12 cells (7) transfected with the Shb cDNA. We have observed expression of various Shb isoforms corresponding to molecular weights of 5 5, 5 9, 66, and 77 kD (6,7). The pancreatic islets studied here expressed primarily the 55-59 kDa Shb isoforms. Surprisingly, the modest increase in the level of Shb expression detected in the Shb-transgenic islets was greatly accentuated by preincubation of the islets with the protease inhibitor N-acetylleu-leu-norleucinal prior to SDS-gel electrophoresis. A Shb is an adaptor protein involved in tyrosine kinase signaling (3, 4) , and on the basis of most of the knowledge accumulated in this field of research, one would expect Shb to be involved in one or several aspects of cell proliferation, differentiation, migration, and survival (21 Insulin secretion in response to glucose in vitro was also enhanced and appears to at least partly reflect an increased islet (3-cell mass with concomitant increases in insulin and DNA content. On the other hand, there may be an actual sensitization of the secretory machinery in response to glucose as well, and this could also be operating in vivo. Thus, the enhanced glucose disappearance after glucose injections could partly derive from an increased X3-cell mass, but could also reflect a sensitized secretory machinery.
The 
